News | March 25, 2026
ImmunityBio scores first Asian approval for ANKTIVA in Macau
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
Olverembatinib, a novel drug developed by Ascentage Pharma with support from the National Major New Drug Development program
Subscribe To Our Newsletter & Stay Updated
